Toxicity and Efficacy Evaluation of an Adeno-Associated Virus Vector Expressing Codon-Optimized RPGR Delivered by Subretinal Injection in a Canine Model of X-linked Retinitis Pigmentosa
- 1 February 2020
- journal article
- research article
- Published by SAGE Publications in Human Gene Therapy
- Vol. 31 (3-4) , 253-267
Abstract
Applied Genetic Technologies Corporation (AGTC) is developing a recombinant adeno-associated virus (rAAV) vector AGTC-501, also designated rAAV2tYF-GRK1-hRPGRco, to treat X-linked retinitis pigmentosa (XLRP) in patients with mutations in the retinitis pigmentosa GTPase regulator (RPGR) gene. The vector contains a codon-optimized human RPGR cDNA (hRPGRco) driven by a photoreceptor-specific promoter (G protein-coupled receptor kinase 1 [GRK1]), and is packaged in an AAV2 capsid variant with three surface tyrosine residues changed to phenylalanine (AAV2tYF). We conducted a toxicity and efficacy study of this vector administered by subretinal injection in the naturally occurring RPGR mutant (X-linked progressive retinal atrophy 2 [XLPRA2]) dog model. Sixteen RPGR mutant dogs divided into four groups of three to five animals each received either a subretinal injection of 0.07 mL of AGTC-501 at low (1.2 × 1011 vector genome [vg]/mL), mid (6 × 1011 vg/mL), or high dose (3 × 1012 vg/mL), or of vehicle control in the right eye at early-stage disease. The left eye remained untreated. Subretinal injections were well tolerated and were not associated with systemic toxicity. Electroretinography, in vivo retinal imaging, and histological analysis showed rescue of photoreceptor function and structure in the absence of ocular toxicity in the low- and mid-dose treatment groups when compared with the vehicle-treated group. The high-dose group showed evidence of both photoreceptor rescue and posterior segment toxicity. These results support the use of AGTC-501 in clinical studies with patients affected with XLRP caused by RPGR mutations and define the no-observed-adverse-effect level at 6 × 1011 vg/mL.Keywords
This publication has 39 references indexed in Scilit:
- Mutations inRPGRandRP2Account for 15% of Males with Simplex Retinal Degenerative DiseaseInvestigative Ophthalmology & Visual Science, 2012
- Gene therapy rescues photoreceptor blindness in dogs and paves the way for treating human X-linked retinitis pigmentosaProceedings of the National Academy of Sciences, 2012
- Misexpression of the Constitutive Rpgrex1-19Variant Leads to Severe Photoreceptor DegenerationInvestigative Ophthalmology & Visual Science, 2011
- Preclinical Evaluation of a Recombinant Adeno-Associated Virus Vector Expressing Human Alpha-1 Antitrypsin Made Using a Recombinant Herpes Simplex Virus Production MethodHuman Gene Therapy, 2010
- rAAV2/5 gene-targeting to rods:dose-dependent efficiency and complications associated with different promotersGene Therapy, 2010
- Scalable Recombinant Adeno-Associated Virus Production Using Recombinant Herpes Simplex Virus Type 1 Coinfection of Suspension-Adapted Mammalian CellsHuman Gene Therapy, 2009
- An efficient rHSV-based complementation system for the production of multiple rAAV vector serotypesGene Therapy, 2008
- Identification and characterization of a novel RPGR isoform in human retinaHuman Mutation, 2007
- Application of a New Subretinal Injection Device in the DogCell Transplantation, 2006
- A Comprehensive Mutation Analysis of RP2 and RPGR in a North American Cohort of Families with X-Linked Retinitis PigmentosaThe American Journal of Human Genetics, 2002